Recombinant Human IFN-lambda 4 Protein, CF

Recombinant Human IFN-lambda 4 (Catalog #9165-IF) exhibits anti-viral activity in HepG2human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC)virus. The ED50 for this effect is 0.2-1.2 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IFN-lambda 4 Protein, CF Summary

• Details of Functionality: Measured in an anti-viral assay using HepG2 human hepatocellular carcinoma cells infected with encephalomyocarditis (EMC) virus. Sheppard, P. et al. (2003) Nat. Immunol. 4:63. The ED₅₀ for this effect is 0.2-1.2 μg/mL.
• Source: E. coli-derived human IFN-lambda 4 protein
  Ala23-Leu179 with an N-terminal Met
• Accession #: K9M1U5
• N-terminal Sequence: Met, Ala23
• Protein/Peptide Type: Recombinant Proteins
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 18 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 19 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Citric Acid and CHAPS.
• Purity: >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IFN-lambda 4 Protein, CF

• IFNAN
• IFNL4
• IFNlambda 4
• IFN-lambda 4

Background

Interferon-lambda 4 (IFN-lambda 4) is a secreted, approximately 17 kDa member of the type III interferon family of molecules (1). It is generated by a frameshift mutation based on a TT > ∆G polymorphism (2). The TT allele inactivates expression of IFN-lambda 4 (2). The ∆G allele is associated with reduced clearance of hepatitis C virus and reduced degranulation of CTL, NK, and NKT cells in the liver during hepatitis (2, 3), although IFN- lambda 4 itself shows in vitro activity against hepatitis C virus (4). IFN-lambda 4 is expressed in the liver of some chronic hepatitis C patients (5). It signals through a receptor complex containing IL-28 R/IFN-lambda R1 and IL-10 R beta to induce the expression of several interferon stimulated genes (ISG) (2, 4). Alternative splicing generates additional isoforms with large internal deletions or a substituted C-terminal region.

1. Wack, A. et al. (2015) Nat. Immunol. 16:802.
2. Prokunina-Olsson, L. et al. (2013) Nat. Genet. 45:164.
3. Jouvin-Marche, E. et al. (2014) J. Infec. Dis. 209:1907.
4. Hamming, O.J. et al. (2013) EMBO J. 32:3055.
5. Amanzada, A. et al. (2013) PLoS One 8:e84026.

Publications for IFN-lambda 4 (9165-IF)(6)

Publications using 9165-IF

• M De, A Bhushan, WS Grubbe, S Roy, JL Mendoza, S Chinnaswam Distinct molecular phenotypes involving several human diseases are induced by IFN-lambda3 and IFN-lambda4 in monocyte-derived macrophages Genes and immunity, 2022-02-03;0(0):. 2022-02-03 [PMID: 35115664] (Bioassay, Human)
• M Lunova, J Kubovciak, B Smolková, M Uzhytchak, K Michalova, A Dejneka, P Strnad, O Lunov, M Jirsa Expression of Interferons Lambda 3 and 4 Induces Identical Response in Human Liver Cell Lines Depending Exclusively on Canonical Signaling International Journal of Molecular Sciences, 2021-03-04;22(5):. 2021-03-04 [PMID: 33806448] (Bioassay, Human)
• M De, A Bhushan, S Chinnaswam Monocytes differentiated into macrophages and dendritic cells in the presence of human IFN-&amp;lambda3 or IFN-&amp;lambda4 show distinct phenotypes J Leukoc Biol, 2020-11-17;0(0):. 2020-11-17 [PMID: 33205487] (Cell Culture, Human)
• JH Chung, SH Hong, N Seo, TS Kim, HJ An, P Lee, EC Shin, HM Kim Structure-based glycoengineering of interferon lambda 4 enhances its productivity and anti-viral potency Cytokine, 2019-08-31;125(0):154833. 2019-08-31 [PMID: 31479875] (Bioassay, Biolayer Interferometry (BLI), Human)
• EA Caine, SM Scheaffer, N Arora, K Zaitsev, MN Artyomov, CB Coyne, KH Moley, MS Diamond Interferon lambda protects the female reproductive tract against Zika virus infection Nat Commun, 2019-01-17;10(1):280. 2019-01-17 [PMID: 30655513] (Bioassay, Human)
• AA Obajemu, N Rao, KA Dilley, JM Vargas, F Sheikh, RP Donnelly, RS Shabman, EG Meissner, L Prokunina-, OO Onabajo IFN-?4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling J. Immunol., 2017-10-25;0(0):. 2017-10-25 [PMID: 29070670] (Bioassay, Human)

Bioinformatics

• Uniprot:
  • K9M1U5()